Trial Type: Gastrointestinal

LS-P-MAST
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Trial Type: Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Musculoskeletal, Skin, Thoracic
Contact: Almhanna, Khaldoun
kalmhanna@BrownHealth.org
LS-P-HEAT
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Trial Type: Endocrine Neuroendocrine, Gastrointestinal, Head and Neck
Contact: Birnbaum, Ariel
abirnbaum@BrownHealth.org
BH-P-LUCERNA
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
araufi2@BrownHealth.org
LS-P-AMORE
Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Breakstone, Rimini
rimini.breakstone@BrownHealth.org
LS-P-GO44479
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
araufi2@BrownHealth.org
BH-P-ENACT
A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
araufi2@BrownHealth.org
SWOGS2205
Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
Protocol Status: OPEN TO ACCRUAL
Trial Type: Breast, Endocrine Neuroendocrine, Eye, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lymphoma, Musculoskeletal, Neurologic, Skin, Thoracic, Unknown Primary
Contact: Graff, Stephanie
sgraff1@BrownHealth.org
LS-P-PRIMROSE
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumors That Are MTAP Deficient
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal, Genitourinary, Head and Neck, Thoracic
Contact: Carneiro, Benedito
benedito.carneiro@BrownHealth.org
LS-P-OCEAN
A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Breakstone, Rimini
rimini.breakstone@BrownHealth.org
LS-P-PATH
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal, Thoracic
Contact: Safran, Howard
hsafran@BrownHealth.org